Re: Farmas USA
"We see the clinical hold as mainly a drug-drug interaction issue rather than a safety concern,"...
Tuesday, July 2, 2:36 PM ET
"We see the clinical hold as mainly a drug-drug interaction issue rather than a safety concern," Leerink's Howard Liang says, regarding the clinical hold on sovaprevir (previous) that has shares of Achillion Pharmaceuticals (ACHN -25.2%) reeling. SA contributor PropThink is inclined to agree, calling the negativity "overdone" and noting that the ongoing Phase II trial of sovaprevir and ACH-3102 — which Liang calls "the more important asset in the portfolio" — has not been halted.
http://seekingalpha.com/currents/post/1118242?source=email_rt_mc_readmore
ACHN